Resmetirom, sold under the brand name Rezdiffra, is a medication used to treat a form of fatty liver disease. Specifically it is used in the treatment of non cirrhotic metabolic dysfunction associated …

Mar 18, 2025 · Resmetirom (Rezdiffra) is used to treat nonalcoholic steatohepatitis (NASH) in adults with moderate to advanced liver scarring (fibrosis) but not with cirrhosis of the liver. It is a tablet …

Today, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver...

Jan 1, 2026 · Resmetirom is used together with diet and exercise to treat non-alcoholic steatohepatitis with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.

Aug 26, 2024 · Find patient medical information for Rezdiffra (resmetirom) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings

Feb 7, 2024 · Resmetirom is an oral, liver-directed, thyroid hormone receptor beta–selective agonist in development for the treatment of NASH with liver fibrosis.

Resmetirom is used for treatment of patients with nonalcoholic steatohepatitis (NASH; liver inflammation and damage caused by buildup of fat in the liver). Resmetirom is in a class of medications called …

Resmetirom is a thyroid hormone receptor (THR)-beta partial agonist.

Oct 17, 2024 · Rezdiffra (resmetirom) is an FDA-approved oral medication used in adults to treat nonalcoholic steatohepatitis (NASH) with liver scarring without cirrhosis. It's the first of its kind to treat …

Resmetirom is an OATP1B1 and OATP1B3 substrate; concomitant use with OATP1B1 and OATP1B3 inhibitors (e.g., cyclosporine) may increase the maximum concentrations and AUC of resmetirom, …